삼진제약

005500KOSPI

66.5 / 100

Reference Date: 2026-10-23

Financial Score31.0 / 40

News Sentiment12.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Rose 5.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samjin Pharmaceutical operates a diverse portfolio spanning OTC drugs, specialty pharmaceuticals, and APIs, leveraging its competitive edge in the pharmaceutical market. The company focuses on developing innovative treatments for age-related diseases and metabolic disorders, with key products including the anticoagulant 'Plaeris' and analgesic 'Geborin'. It is expanding into health foods and medical devices, and has enhanced its global production capabilities through the 2022 completion of its Osong facility.

Number of Employees

819people

Average Salary

81.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.95Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.90Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

8.76Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

11.36Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲19.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 10.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (32%)

Current 19,540Won52-week high 24,70052-week low 17,010

1-month return4.0Point

1m +5.62% (slight rise)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0